Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins? A French nationwide cohort study based on national administrative databases

被引:61
作者
Fagot, Jean-Paul [1 ]
Blotiere, Pierre-Olivier [1 ]
Ricordeau, Philippe [1 ]
Weill, Alain [1 ]
Alla, Francois [2 ]
Allemand, Hubert [2 ]
机构
[1] Natl Hlth Insurance, Strategy & Res Dept, Paris, Ile De France, France
[2] Natl Hlth Insurance, Gen Div, Paris, Ile De France, France
关键词
SHORT-TERM INCIDENCE; FOLLOW-UP; MALIGNANCIES; BREAST; ANALOGS; TIME;
D O I
10.2337/dc12-0506
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-To explore in France the relationship between insulin glargine use and overall and specific cancer risks in type 2 diabetic patients compared with other basal insulins. RESEARCH DESIGN AND METHODS-Data were extracted from French health insurance information system (Systeme National d'Information Inter-Regimes de l'Assurance Maladie) linked with data from the French Hospital Discharge database (Programme de Medicalisation des Systemes d'Information). Included were 70,027 patients aged 40-79 years who started a basal insulin in 2007-2009. Cox proportional hazards models with age as time-scale were used to calculate multivariate-adjusted hazard ratios for associations between type of basal insulin and risk of overall cancer, breast cancer, and seven other cancer sites. RESULTS-The median follow-up was 2.67 years in patients exposed to insulin glargine. Absolute event rates for all cancer in patients exposed to glargine versus other basal insulin users were 1,622 and 1,643 per 100,000 person-years, respectively. No significant association was observed between glargine exposure and overall cancer incidence after adjustment for sex, with a hazard ratio of 0.97 (95% CI 0.87-1.07), or after additional adjustment for any other hypoglycemic agent use and duration of diabetes. No increased risk of breast cancer was observed for glargine users compared with other basal insulins users, with a fully adjusted hazard ratio of 1.08 (0.72-1.62). CONCLUSIONS-In a large cohort of patients newly treated by basal insulin, no increased risk of any cancer was observed in insulin glargine users compared with other basal insulin users. Because follow-up did not exceed 4 years, longer-term studies are needed. Diabetes Care 36:294-301, 2013
引用
收藏
页码:294 / 301
页数:8
相关论文
共 29 条
[21]   Insulin glargine and malignancy: an unwarranted alarm [J].
Pocock, Stuart J. ;
Smeeth, Liam .
LANCET, 2009, 374 (9689) :511-513
[22]   Is it possible to estimate the incidence of breast cancer from medico-administrative databases? [J].
Remontet, L. ;
Mitton, N. ;
Couris, C. M. ;
Iwaz, J. ;
Gomez, F. ;
Olive, F. ;
Polazzi, S. ;
Schott, A. M. ;
Trombert, B. ;
Bossard, N. ;
Colonna, M. .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2008, 23 (10) :681-688
[23]   Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study [J].
Ruiter, R. ;
Visser, L. E. ;
van Herk-Sukel, M. P. P. ;
Coebergh, J. W. W. ;
Haak, H. R. ;
Geelhoed-Duijvestijn, P. H. ;
Straus, S. M. J. M. ;
Herings, R. M. C. ;
Stricker, B. H. Ch .
DIABETOLOGIA, 2012, 55 (01) :51-62
[24]   Long-term effects of insulin glargine on the risk of breast cancer [J].
Suissa, S. ;
Azoulay, L. ;
Dell'Aniello, S. ;
Evans, M. ;
Vora, J. ;
Pollak, M. .
DIABETOLOGIA, 2011, 54 (09) :2254-2262
[25]   Glargine Promotes Proliferation of Breast Adenocarcinoma Cell Line MCF-7 via AKT Activation [J].
Teng, J. -A. ;
Hou, R. -L. ;
Li, D. -L. ;
Yang, R. -P. ;
Qin, J. .
HORMONE AND METABOLIC RESEARCH, 2011, 43 (08) :519-523
[26]   French national health insurance information system and the permanent beneficiaries sample [J].
Tuppin, P. ;
de Roquefeuil, L. ;
Weill, A. ;
Ricordeau, P. ;
Merliere, Y. .
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2010, 58 (04) :286-290
[27]   Implantation and patient profiles for pacemakers and cardioverter-defibrillators in France (2008-2009) [J].
Tuppin, Philippe ;
Neumann, Anke ;
Marijon, Eloi ;
de Peretti, Christine ;
Weill, Alain ;
Ricordeau, Philippe ;
Danchin, Nicolas ;
Allemand, Hubert .
ARCHIVES OF CARDIOVASCULAR DISEASES, 2011, 104 (05) :332-342
[28]   Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data [J].
van Staa, T. P. ;
Patel, D. ;
Gallagher, A. M. ;
de Bruin, M. L. .
DIABETOLOGIA, 2012, 55 (03) :654-665
[29]   Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus [J].
Weill, Alain ;
Paita, Michel ;
Tuppin, Philippe ;
Fagot, Jean-Paul ;
Neumann, Anke ;
Simon, Dominique ;
Ricordeau, Philippe ;
Montastruc, Jean-Louis ;
Allemand, Hubert .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (12) :1256-1262